Intrexon Corporation through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
September 23, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
August 23, 2021
RegMed Investors’ (RMi) pre-open: market gained after loses while sector gained; what’s next?
December 24, 2020
Happy Hanukkah and a Merry Christmas as the NEW Year 2021 approaches
May 30, 2020
RegMed/Cell and Gene Therapy Earnings Scorecard - Q1/20 - to date
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
February 17, 2020
RegMed Investors’ (RMi) closing bell: markets are closed for President's Day holiday
February 5, 2020
RegMed Investors’ (RMi) closing bell: expectation, a strong belief that something will happen or be the case in the future
February 4, 2020
RegMed Investors’ (RMi) closing bell: the sector soars
February 3, 2020
RegMed Investors’ (RMi) closing bell: the return of the oversold from the coronavirus influence
January 25, 2020
RegMed Investors' (RMi) closing bell: which risks are playing-out that haven't already been there?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Intrexon (NYSE: XON) – Opened 2018 at $13.47, started February at $13.21 and March at $12.90 seeing a high on 3/6 at $15.63. Over last year, the stock declined 45.2%, as against the industry’s gain of 0.1% while developing several candidates in partnership with other companies. Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide XON with funds in the form of technology access fees along with milestones and other payments. News is always a stimulant to BUY and SELL ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors